EOLS - רווח נקי למניה (EPS TTM) Evolus, Inc.

Evolus, Inc. (EOLS) focuses on training sales specialists and retaining key experts. The current annual net income per unit visualizes these successes, where -0.47 serves as the base parameter value. Stability is ensured by an advanced cold chain logistics system, while the environmental strategy is implemented through the reduction of plastic packaging and the optimization of energy costs during drug production.

TTM net income per share measures the ultimate business efficiency by allocating total annual income per common share to assess the real return on equity. The growth in TTM annual earnings per share for Evolus, Inc. (EOLS) confirms that expansion through the hiring of top-tier aesthetic medicine sales specialists is transforming operating expenses into sustainable financial results.